Perrigo Company plc

Perrigo Company plc

PRGONYSE / NASDAQHealthcareSmall cap

$15.94-$0.10 (-0.6%)

Last close · Data as of Nov 20, 2026

Market cap
$1.5B
P/E
-1.0x
EV / EBITDA
-5.7x
Revenue
$4.3B
Net margin
-33.5%
ROCE
4.2%

+30.0% over the last year

Perrigo Company plc price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.4%
3M
+16.4%
6M
+42.8%
1Y
+30.0%
5Y
-61.3%

52-week range

Day change -$0.10 (-0.6%) from $16.04 to $15.94 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PRGO, bought on each weekday since 2021.

News & filings

What Perrigo Company filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 1.4 billion US dollars in fiscal 2025.

Strengths (1)

  • The price is 26.8% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

Read moreShow less

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Sector
Healthcare
Shares outstanding
137.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.5B
P/E
-1.0x
P/B
0.5x
EV / EBITDA
-5.7x
EV / Sales
1.1x
P/S
0.3x
52-week high
$16.95
52-week low
$9.25

Profitability

Operating margin
7.4%
Net margin
-33.5%
EBITDA margin
-18.8%
ROE
-48.6%
ROCE
4.2%
ROA
-16.7%
Asset turnover
0.50

Growth

Revenue
$4.3B
Revenue growth, 1Y
-2.8%
Revenue CAGR, 3Y
-1.5%
Net profit growth, 1Y
729.7%
Free cash flow
$145.1M

Solvency

Current ratio
2.76
Debt / Equity
1.24
Debt / Assets
0.43
CFO / Net profit
-0.17
Cash / Market cap
36.0%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$4.3B
Cost of revenue$2.8B
Gross profit$1.5B
Operating expenses$1.2B
Research and development$95.4M
Selling, general and administrative$1.1B
Operating income$312.8M
Interest and other-$1.6B
Pretax income-$1.3B
Tax and other$127.5M
Net income-$1.4B

Revenue and net profit

Revenue fell 2.8% in FY2025; net profit is the dashed line.

Perrigo Company plc revenue and net profit by fiscal year
Perrigo Company plc revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$4.5B-$140.6M
FY2023$4.7B-$12.7M
FY2024$4.4B-$171.8M
FY2025$4.3B-$1.4B

Cash flows

FY2025: $238.5M from operations, $145.1M free after investment (dashed).

Perrigo Company plc operating and free cash flow by fiscal year
Perrigo Company plc operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$307.3M$210.9M
FY2023$405.5M$303.8M
FY2024$362.9M$244.6M
FY2025$238.5M$145.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$4.3B-2.8%1Y
EBITDA
-$797.9M-284.3%1Y
Net profit
-$1.4B
Cash from operations
$238.5M-34.3%1Y
Free cash flow
$145.1M-40.7%1Y
Revenue CAGR, 3Y
-1.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$4.3B-$797.9M-$1.4B$145.1M-48.6%-2.8%+729.7%

Monthly returns

Month-by-month returns of PRGO across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$8.5B
Liabilities$5.6B
Equity$2.9B
Retained earnings-$3.7B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PRGO highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Perrigo Company plc (this company)1.1x

Not shown (no positive earnings and no EV / Sales): MBX Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Perrigo Company plcPRGOthis company$1.5B-1.0x0.5x-48.6%-5.7x
PROCEPT BioRobotics CorporationPRCT$1.5B-16.1x4.2x-26.1%-15.6x
AnaptysBio, Inc.ANAB$1.5B—40.4x-35.6%17.4x
STAAR Surgical CompanySTAA$1.5B-18.5x4.3x-23.4%-36.9x
NeoGenomics, Inc.NEO$1.5B-13.6x1.8x-12.9%-44.5x
MBX Biosciences, Inc.MBX$1.5B-16.9x4.0x-23.6%-14.3x
Monte Rosa Therapeutics, Inc.GLUE$1.5B-38.0x6.3x-16.6%-30.0x
Aveanna Healthcare Holdings Inc.AVAH$1.4B6.4x7.4x115.3%10.3x
Septerna, Inc.SEPN$1.4B-28.9x3.7x-12.8%-16.6x
Peer median—-16.9x4.3x-20.0%-16.1x

Year-to-date ROI

PRGO since 1 January, against earlier years.

Historical volatility

PRGO's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Perrigo Company plc operating margin by fiscal year
Perrigo Company plc operating margin by fiscal year
DateOperating margin
FY20222.7%
FY20236.1%
FY20247.1%
FY20257.4%
LineFY2025
Cost of revenueCost Of Revenue$2.8B
Gross profitGross Profit$1.5B
Operating expensesOperating Expense$1.2B
Research and developmentResearch And Development$95.4M
Other operating expensesOther Operating Expenses$30.5M
Total expensesTotal Expenses$3.9B
Pretax incomePretax Income-$1.3B

Learn while you research

Academy chapters picked for Perrigo Company plc and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →